Gender-Responsive Drug Use Treatment for Juvenile Justice Girls
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 12 - 24 |
Updated: | 12/27/2018 |
Start Date: | September 2014 |
End Date: | August 2020 |
Contact: | Marina Tolou-Shams, Ph.D. |
Email: | marina.tolou-shams@ucsf.edu |
Phone: | 415-206-2212 |
Girls in the juvenile justice system have unique developmental pathways to drug use and
co-occurring risk (e.g., HIV/STI) behaviors that have typically not been considered or tested
in order to identify evidence-based gender-specific substance use treatment approaches for
this population. This study will advance scientific knowledge and clinical practice in the
drug treatment and public health fields by testing the efficacy of a pre-existing, widely
disseminated gender-responsive substance use treatment (VOICES) on drug use and HIV/STI risk
behavior outcomes for a broad range of substance using girls and young women (ages 12-24) who
are at-risk for or already involved with the justice system.
co-occurring risk (e.g., HIV/STI) behaviors that have typically not been considered or tested
in order to identify evidence-based gender-specific substance use treatment approaches for
this population. This study will advance scientific knowledge and clinical practice in the
drug treatment and public health fields by testing the efficacy of a pre-existing, widely
disseminated gender-responsive substance use treatment (VOICES) on drug use and HIV/STI risk
behavior outcomes for a broad range of substance using girls and young women (ages 12-24) who
are at-risk for or already involved with the justice system.
Compared to both non-offending females and male offending counterparts, offending girls are
at significantly greater risk for the development of substance use disorders, psychiatric
symptoms and negative health outcomes, such as HIV/AIDS or other sexually transmitted
infections (STIs). Research suggests that girls may have different developmental pathways to
drug use, initial legal involvement and co-occurring negative health outcomes that support
the importance of testing gender-specific treatments for juvenile justice girls. Although
there is recent increased emphasis on gender-specific programming in juvenile justice,
empirically supported gender specific interventions to improve health, mental health and/or
legal outcomes among juvenile justice girls are lacking. The objective of this Stage II
treatment trial is therefore to test the efficacy of a pre-existing, widely disseminated
gender-responsive drug use treatment (VOICES) among 130 girls who are at-risk for or already
involved with the justice system. We seek to test the effect of VOICES on girls' drug and
alcohol use, HIV/STI risk, psychiatric symptoms and recidivism as well as explore moderators
and mediators of outcomes. Girls and young women, ages 12-24 (N= 6 juveniles for Phase I
Intervention Run-Through; N=130 for Phase II RCT study) will be recruited from justice
partners (probation, diversion programs) and school partners (high schools/middle schools).
Participants will be randomized to either the VOICES (active) intervention (n=65) or a Girl
Health (attention control) condition (n=65). In Phase I (first six months of Year 1), 6
juveniles will be recruited to complete the Intervention Run-Through and research assessment
once to allow testing of RCT intervention and assessment procedures prior to the RCT phase.
In Phase II (last half of Year 1 through Year 4), 130 girls will be recruited and randomized
at baseline and then re-assessed at mid-treatment, end of treatment, 3 months and 6 months
post-intervention. Biological specimens for juvenile drug use will also be collected at each
3-month assessment. Efficacy trial results can be used to make immediate changes to current
widespread program delivery resulting in direct impact on the field of evidence-based
gender-responsive substance use interventions for juvenile justice girls and young women.
at significantly greater risk for the development of substance use disorders, psychiatric
symptoms and negative health outcomes, such as HIV/AIDS or other sexually transmitted
infections (STIs). Research suggests that girls may have different developmental pathways to
drug use, initial legal involvement and co-occurring negative health outcomes that support
the importance of testing gender-specific treatments for juvenile justice girls. Although
there is recent increased emphasis on gender-specific programming in juvenile justice,
empirically supported gender specific interventions to improve health, mental health and/or
legal outcomes among juvenile justice girls are lacking. The objective of this Stage II
treatment trial is therefore to test the efficacy of a pre-existing, widely disseminated
gender-responsive drug use treatment (VOICES) among 130 girls who are at-risk for or already
involved with the justice system. We seek to test the effect of VOICES on girls' drug and
alcohol use, HIV/STI risk, psychiatric symptoms and recidivism as well as explore moderators
and mediators of outcomes. Girls and young women, ages 12-24 (N= 6 juveniles for Phase I
Intervention Run-Through; N=130 for Phase II RCT study) will be recruited from justice
partners (probation, diversion programs) and school partners (high schools/middle schools).
Participants will be randomized to either the VOICES (active) intervention (n=65) or a Girl
Health (attention control) condition (n=65). In Phase I (first six months of Year 1), 6
juveniles will be recruited to complete the Intervention Run-Through and research assessment
once to allow testing of RCT intervention and assessment procedures prior to the RCT phase.
In Phase II (last half of Year 1 through Year 4), 130 girls will be recruited and randomized
at baseline and then re-assessed at mid-treatment, end of treatment, 3 months and 6 months
post-intervention. Biological specimens for juvenile drug use will also be collected at each
3-month assessment. Efficacy trial results can be used to make immediate changes to current
widespread program delivery resulting in direct impact on the field of evidence-based
gender-responsive substance use interventions for juvenile justice girls and young women.
Inclusion Criteria:
130 court-involved, non-incarcerated (CINI) female juvenile offenders or those at-risk for
court-involvement, ages 12-24, who report any alcohol, marijuana or other drug use in the
past 90 days will be eligible for enrollment with the following criteria:
1) Determined to be in need of substance use treatment by the court intake worker,
probation officer, presiding judge or magistrate, and/or school counselor; 2) Legal
guardian available to consent for child's participation, if the child is under the age of
18, and 3) Child is English speaking.
Exclusion Criteria:
1. meet DSM-V criteria for substance use disorder with current severity rating of severe
(6 or more symptoms) (as determined through referral partner);
2. already in substance use treatment (residential or outpatient) and wish to remain with
outside provider (as determined through referral partner);
3. observable cognitive or developmental delays or active psychosis that would interfere
with completing consent, assessment or intervention.
We found this trial at
1
site
San Francisco, California 94110
Principal Investigator: Marina Tolou-Shams, PhD
Phone: 415-206-6196
Click here to add this to my saved trials